ASND
Ascendis Pharma A/S
There isn't enough reported data to score ASND yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ASND Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Under pressure | |
| Strong |
ASND's profitability and balance sheet are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its revenue.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ASND PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $267 | — |
| Cheap | 22x | $313 | +17% |
| Fair | 27x | $388 | +45% |
| Expensive | 29x | $428 | +60% |
Historical ranges are pointers, not guarantees.
ASND's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ASND in the historical PE scenario, which offers more potential upside but is not a forecast.
ASND Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ASND, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ASND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $14.54 | +$18.78 |
| Q4 2025 | -$4.18 | +$3.07 |
| Q3 2025 | -$4.24 | +$4.05 |
| Q2 2025 | -$5.04 | +$4.54 |
| Q1 2025 | -$6.45 | +$3.41 |
| Q4 2024 | -$7.25 | +$2.25 |
| Q3 2024 | -$8.29 | +$3.61 |
| Q2 2024 | -$9.58 | +$2.49 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 125% for ASND versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ASND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +347% |
| Q4 2025 | $274.9M | +42% |
| Q3 2025 | $237.3M | +269% |
| Q2 2025 | $175.6M | +339% |
| Q1 2025 | $112.1M | +5.3% |
| Q4 2024 | $193.2M | +26% |
| Q3 2024 | $64.2M | +20% |
| Q2 2024 | $40M | -24% |
ASND has the stronger quarterly revenue trend. Revenue is up 847% for ASND versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +142 points |
| Q4 2025 | 4% | +3.8 points |
| Q3 2025 | 5.2% | +172 points |
| Q2 2025 | -34% | +337 points |
| Q1 2025 | -103% | -52 points |
| Q4 2024 | 0.2% | +27 points |
| Q3 2024 | -167% | +113 points |
| Q2 2024 | -370% | -73 points |
ASND has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ASND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$62.9M | +$76.8M |
| Q2 2024 | -$68.5M | +$102.1M |
| Q1 2024 | -$113.1M | +$51.5M |
| Q4 2023 | -$47.1M | +$114.5M |
| Q3 2023 | -$139.6M | -$26.3M |
| Q2 2023 | -$170.6M | -$28.3M |
| Q1 2023 | -$164.6M | -$15M |
| Q4 2022 | -$161.6M | -$19.3M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with ASND at up 36%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ASND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +6.2M shares |
| 1 year | +11% | +6.8M shares |
| 3 years | +19% | +10.7M shares |
| 5 years | +24% | +13M shares |
| Available history | +42% | +19.6M shares |
ASND has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $173.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $19.3M |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $2,222 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ASND Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
ASND has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ASND on leverage, with a lower net debt burden relative to earnings.
ASND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 73.4 | Neutral |
ASND's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ASND PE vs Healthcare Sector
| Metric | ASND | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 4 | 29 | 25 pts below |
ASND is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ASND on valuation relative to its sector.
ASND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $240.8 | 11% above |
| 20 week MA | $250.3 | 6.7% above |
| 50 week MA | $235.2 | 14% above |
| 100 week MA | $202.9 | 32% above |
| 200 week MA | $160.1 | 67% above |
ASND is in an uptrend: it's above all five of its weekly moving averages, and 67% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ASND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.1 | $170.9 | +27% |
| 2021 | $170.9 | $139.3 | -18% |
| 2022 | $139.3 | $119.1 | -15% |
| 2023 | $119.1 | $126.0 | +5.8% |
| 2024 | $126.0 | $137.5 | +9.2% |
| 2025 | $137.5 | $209.0 | +52% |
| 2026 YTD | $209.0 | $267.1 | +28% |
ASND has finished higher in four of the last six years. It's up 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ASND on returns for 2026, with the stronger performance.